Biocare Medical, LLC is pleased to announce a sampling program for p63 antibody for clinical and research laboratories. Biocare Medical is currently one of only two companies worldwide with rights to sell p63 antibodies for IVD testing purposes. Customers can go to Biocare.net/p63 to sign up for a low cost evaluation sample. Both predilute and concentrated antibodies are available.
Biocare announced the favorable resolution of a challenge to its non-exclusive worldwide license for p63 antibodies in 2008. The United States District Court’s ruling in favor of Biocare reinforced and confirmed its right to “make, use or sell” IVD p63 antibodies, which makes use of discoveries made at Harvard University and covered under United States patent nos. 6,946,256 and 7,030,227. A subsequent appeal of that ruling was unsuccessful and did not alter Biocare’s license agreement with Harvard. Moreover, customers should ignore any press releases by competitors that announce an “exclusive” license or distributorship agreement for p63 as they are untrue.
p63 is also featured in several of Biocare’s novel multiplex IHC products. PIN-4™, ADH-5™, Lung Adeno-2™ and Lung Sqamous-2™ help to differentiate: five phenotypes of breast cancer; PIN vs. prostate cancer vs. benign disease; and lung adeno- vs. squamous cell carcinoma.
Laboratories may contact their local Biocare Medical Sales Representative or distributor for more information or visit http://www.biocare.net/p63
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC tests which provide increased confidence at critical diagnostic decision points, impacting patient therapy while accelerating turnaround time. Biocare’s advanced micro-polymer™ detection enables unsurpassed specificity and sensitivity. PROMARK™ and “mouse on mouse” IHC detection kits are optimized for rat and mouse tissues and feature proprietary blocking and retrieval reagents, resulting in virtually background free IHC staining.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets with novel tissue immunohistochemistry and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Posted By: Biocare Medical On: 06-Jul-2010